Argenx has filed a patent for a combination therapy using an antibody binding to CD70 and a BCL-2 inhibitor, potentially treating myeloid malignancies like AML. The combination, including ARGX-110 and venetoclax, shows synergistic effects in certain embodiments. GlobalData’s report on Argenx gives a 360-degree view of the company including its patenting strategy. Buy the report here.

Smarter leaders trust GlobalData


Data Insights Argenx SE - Company Profile

Buy the Report

Data Insights

The gold standard of business intelligence.

Find out more

According to GlobalData’s company profile on Argenx, Personalized cancer vaccines was a key innovation area identified from patents. Argenx's grant share as of January 2024 was 32%. Grant share is based on the ratio of number of grants to total number of patents.

Combination for treating myeloid malignancy with cd70 antibody and bcl-2 inhibitor

Source: United States Patent and Trademark Office (USPTO). Credit: Argenx SE

The patent application (Publication Number: US20240033353A1) discloses a combination therapy for the treatment of acute myeloid leukemia (AML) comprising an antibody or antigen binding fragment that binds to CD70 and a BCL-2 inhibitor, specifically Compound (I). The antibody targeting CD70 includes specific CDR sequences and can be an IgG with various activities such as ADCC, CDC, or ADCP. Additionally, the antibody may be defucosylated or specifically identified as ARGX-110 (cusatuzumab). The combination may also include other anti-cancer agents, such as hypomethylating agents like azacitidine or decitabine, to enhance the treatment efficacy.

Furthermore, the patent application details the formulation of the antibody or antigen binding fragment and the BCL-2 inhibitor as separate compositions, highlighting the potential for synergistic treatment effects when administered to human subjects with AML. The combination therapy aims to provide synergistic cell killing when cultured with specific AML cell lines, emphasizing the targeted approach of the treatment. Overall, the disclosed combination therapy presents a promising strategy for the treatment of AML by leveraging the unique properties of the CD70-targeting antibody and the BCL-2 inhibitor to enhance therapeutic outcomes in patients with this challenging disease.

To know more about GlobalData’s detailed insights on Argenx, buy the report here.

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies